# Boehringer Ingelheim

Organization · id `cardio:boehringer-ingelheim` · Cardiovascular Atlas · release `f6f6f1b6f50379ed` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

## In plain language

A pharmaceutical company. It sponsored the EMPEROR-Reduced and EMPEROR-Preserved trials of empagliflozin. The US regulator's record for Jardiance names Boehringer Ingelheim as the sponsor of the application.

## Technical summary

Research Organization Registry record 00q32j219 lists Boehringer Ingelheim (Germany), a company and funder, in Ingelheim. EMPEROR-Reduced (NCT03057977) and EMPEROR-Preserved (NCT03057951) name Boehringer Ingelheim as lead sponsor, with sponsor class industry, and a second drug company as a collaborator. The openFDA record for NDA204629 names BOEHRINGER INGELHEIM as the application sponsor.

## Connected pages

- Manufactures: Empagliflozin (Jardiance) (`cardio:jardiance`)
- Manufactures: Dabigatran (Pradaxa) (`cardio:pradaxa`)
- Sponsors: EMPA-KIDNEY: empagliflozin in a broad range of chronic kidney disease (`cardio:empa-kidney`)
- Sponsors: EMPA-REG OUTCOME: empagliflozin and cardiovascular outcomes in type 2 diabetes (`cardio:empa-reg-outcome`)
- Sponsors: EMPEROR-Preserved (`cardio:emperor-preserved`)
- Sponsors: EMPEROR-Reduced (`cardio:emperor-reduced`)
- Sponsors: RE-LY (`cardio:re-ly`)

## Provenance

Content hash: b78ed21b1887f6ca3a134443aaa83c5d732edede1d544ea5d2bc94c3fb8e8579
Last substantive edit: 2026-10-15
Evidence last checked: 2026-10-14